PALI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
500.0K
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
500.0K
0
0
0
0
Operating Expenses
12.2M
+13.5%
10.7M
+7.7%
10.0M
+241.6%
2.9M
+2.8%
2.8M
R&D
7.4M
+15.7%
6.4M
+3.6%
6.2M
+342.8%
1.4M
-16.8%
1.7M
SG&A
4.8M
+10.3%
4.4M
+14.3%
3.8M
+149.2%
1.5M
+30.8%
1.2M
Operating Income
-11698000
-8.8%
-10748000
-7.7%
-9981000
-241.6%
-2922000
-2.8%
-2843000
EBITDA
-11698000
-8.8%
-10748000
-7.7%
-9981000
-241.7%
-2921000
-2.8%
-2842000
Net Income
-10574000
-10.1%
-9600000
-7.9%
-8899000
-210.3%
-2868000
-3.0%
-2784000
EPS (Basic)
$-0.05
+0.0%
$-0.05
-25.0%
$-0.04
+89.5%
$-0.38
+34.5%
$-0.58
EPS (Diluted)
$-0.05
+0.0%
$-0.05
-25.0%
$-0.04
+89.5%
$-0.38
+34.5%
$-0.58
Shares (Diluted)
211.4M
+0.8%
209.7M
+2.0%
205.6M
+2651.1%
7.5M
+55.8%
4.8M
Palisade Bio (PALI) โ€” Financials